PD-L1 upregulation
IPI201 activates the cGAS–STING/IRF3 innate-immunity pathway, transcriptionally upregulating PD-L1. Validated in vitro and in two syngeneic in vivo models in combination with atezolizumab (Tecentriq).
Pipeline · IPI201
IPI201:
A new class of immunotherapy adjuvant.
An intravenous synthetic small molecule designed to convert immunologically cold, PD-L1-negative tumors into checkpoint-sensitive targets, without competing with the checkpoint inhibitors already on the market.
Development status
Phase I trial initiated. April 2026.
Asset
Indication
Stage
IPI201
IV synthetic small molecule · immunotherapy adjuvant
PD-1 Relapsed or Refractory
Phase I trial
Phase I trial
Preclinical
Phase I
Phase II
Phase III
Approval
IPI301
Dissolving microneedle patch · intradermal delivery
Rapid onset for inflammatory indications
Preclinical
Phase I
Phase II
Phase III
Approval
The thesis
Don't compete with Keytruda. Expand it.
PD-1 checkpoint inhibitors like Keytruda fail to work in the majority of solid tumors. Most patients have cold tumors with low or absent PD-L1 expression, making them ineligible for or unresponsive to checkpoint therapy.
IPI201 is designed to convert this excluded population into checkpoint-sensitive patients by upregulating PD-L1 expression, repolarizing tumor-associated macrophages, reducing inflammatory drivers of immune exclusion, and improving tissue perfusion. The result is an adjuvant strategy that creates new responder populations rather than replacing existing therapies.
Mechanism of action
Cold-to-hot conversion through four convergent pathways.
IPI201 is a multi-target small molecule. Each pathway has been validated in preclinical models. Together, they remodel the tumor microenvironment to restore the conditions under which checkpoint and cellular therapies can work.
Macrophage repolarization
Shifts tumor-associated macrophages from a pro-inflammatory M1 phenotype toward an anti-inflammatory M2 phenotype, reducing the local signals that exclude T cells from the tumor core.
TNF-α and ROS reduction
Reduces TNF-α, reactive oxygen species, and broader inflammatory mediators, restoring anti-tumor immune infiltration so checkpoint therapy can take hold.
Hypoxia reversal & perfusion
Regulates blood flow to enhance reperfusion following hypoxic injury, supporting drug delivery to the tumor and creating adjacent applications in traumatic brain injury and ischemia-related indications.
Clinical validation
Independent human evidence that resistance is reversible.
Two recent clinical readouts in PD-1 refractory triple-negative breast cancer have each demonstrated 50% objective response rates, independent confirmation that the cold-to-hot biology IPI201 targets is real and clinically actionable.
"50% objective response rate in PD-1 refractory TNBC. Directly validating that resistance is convertible in humans and the market opportunity is real."
Cromolyn study, Nature Medicine, June 2025Cromolyn in PD-1 refractory TNBC
50% ORR in PD-1 refractory TNBC, directly validating that checkpoint resistance is convertible in humans through immune microenvironment modulation.
Camrelizumab Phase II
50% ORR in anti-PD-1 refractory TNBC via mast cell mobilization, confirming that checkpoint resistance is reversible with the right adjuvant mechanism.
IPI201 + atezolizumab
IPI201 transcriptionally upregulates PD-L1 via cGAS–STING/IRF3, converting checkpoint-resistant TNBC tumors into atezolizumab-sensitive targets in two syngeneic in vivo models.
Proprietary data
IPI201 + anti-PD-1 in colorectal cancer.
In a colorectal tumor mouse model, IPI201 combined with anti-PD-1 produced synergistic anti-tumor activity across every measured endpoint, outperforming PD-1 monotherapy on survival, necrosis, microenvironment remodeling, and gene-expression modulation.
>60%
Tumor volume reduction vs. PD-1 alone
2×
Tumor necrosis score: ~4/4 vs. ~2/4 for anti-PD-1 alone
71%
Of TME gene-expression changes attributable to the combination
#1
Top-ranked altered pathway: Immune System
"71% of all gene expression changes were exclusively attributable to the IPI201 + anti-PD-1 combination. Strong preclinical evidence that IPI201 can convert PD-1 non-responders into responders."
Internal colorectal tumor mouse model, Isosceles preclinical program
NK cell immunotherapy
A platform enhancer for cellular therapy.
In collaboration with CytoImmune, IPI201 demonstrated a previously unrecognized (and now patented) dual role in NK cell-based immunotherapy: sensitizing colorectal cancer cells to NK killing while independently sustaining NK cell survival.
+625%
Generic NK cytolysis: 2,403 vs. 332 (NK alone) AUC
+50%
TRACK NK (CAR-NK) cytolysis: 3,151 vs. 2,108 AUC
3rd
Known molecule sufficient to sustain NK cell survival in vitro, alongside IL-2 and IL-15
p < 0.05
Dose-dependent NK survival support over 7 days
IPI201 operates through two complementary NK mechanisms: it sensitizes tumor cells to NK-mediated killing, and it independently sustains NK cell viability, addressing one of the central limitations of NK cell therapy, persistence in vivo. This positions IPI201 as a platform enhancer across both checkpoint and cellular immunotherapy modalities.
Development plan
Phase I/II basket trial. Lead indication PD-1 refractory TNBC.
- Stage
- Phase I/II basket trial
- Lead indication
- PD-1 refractory TNBC
- Phase I status
- Initiated, April 2026
Despite transforming outcomes in select cancers, checkpoint immunotherapies still generate objective responses in only about 15–30% of patients across most solid tumor types, leaving the majority as cold, non-responders who represent a major opportunity for agents that can convert their disease into immunologically hot, immunotherapy-sensitive targets.
Note for partners and investors: Partnership economics, formulation advantages (IV synthetic vs. alternative routes), and IP defensibility are available on request. Forward-looking statements regarding clinical timelines are subject to change based on regulatory and operational factors.